INTRODUCTION {#sec1}
============

Biochemical relapse (BR) after a primary radical prostatectomy may occur in up to 40 percent of cases \[[@cit0001]\]. The traditional method of treatment of patients with BR is salvage radiotherapy. In accordance to the European Assosiation of Urology (EAU) Guidelines \[[@cit0002]\], performance of extended pelvic lymphadenectomy (ePLND) is justified in patients with a high-risk localized prostate cancer and with \>5% risk for metastatic progression. Patients with isolated lymph nodes cancer recurrence have a more favorable prognosis as compared to the patients with prostate cancer with bone or internal organs metastasis \[[@cit0003]\]. Salvage lymphadenectomy has been proposed in patients with 'node-only' driven BR, following a definitive treatment of the primary prostate cancer (PCa). This procedure is typically performed by an open surgery with its associated morbidity. In this paper we present our initial series of 10 consecutive patients who underwent an extended robotic salvage pelvic lymph node dissection (eRSPND) for 'node-only' recurrent PCa.

MATERIAL AND METHODS {#sec2}
====================

This was a prospective study, which included patients, who presented with a biochemical relapse after a primary radical prostatectomy at a median of 3.6 years prior ([Table 1](#t0001){ref-type="table"}). Clinical work-up, which was done according to the standard protocol prior 11Choline PET/CT (Positron Emission Tomography/Computed Tomography) including MRI (magnetic resonance imaging of chest/abdomen/pelvis) and a bone scan, did not reveal any abnormalities. All patients underwent 11Choline PET/CT, which identified 'node-only' metastases along the external iliac lymph nodes ([Figure 1](#f0001){ref-type="fig"}), pelvic lymph nodes ([Figure 2](#f0002){ref-type="fig"}) and in a group of obturator lymph nodes on both sides ([Figure 3](#f0003){ref-type="fig"}).

###### 

Baseline demographics

  Demographics                                                                                Median (range) or N (%)
  ------------------------------------------------------------------------------------------- -------------------------
  N                                                                                           10
  Age, years                                                                                  63 (50--71)
  PSA (prostate specific antigen) at initial PCa (primary prostate cancer) diagnosis, ng/ml   8.3 (5.7--13.4)
  Primary Gleason score:                                                                      
  Grade 1                                                                                     0 (0%)
  Grade 2                                                                                     2 (20%)
  Grade 3                                                                                     5 (50%)
  Grade 4                                                                                     3 (30%)
  Grade 5                                                                                     0 (0%)
  TNM (Tumor nodes metastases) stage                                                          
  T2cN0M0                                                                                     8 (80%)
  T3aN0M0                                                                                     2 (20%)
  Prior primary treatment:                                                                    
  Robotic radical prostatectomy (RP)                                                          9 (90%)
  Open RP                                                                                     1 (10%)
  Prior PLND (pelvic lymphadenectomy) (at initial RP)                                         9 (90%)
  Number of nodes                                                                             7 (6-9)
  Time from Primary Treatment, months                                                         44

![Metastases along the external iliac lymph nodes.](CEJU-71-1478-g001){#f0001}

![Metastases in pelvic lymph nodes.](CEJU-71-1478-g002){#f0002}

![Metastases in a group of obturator lymph nodes on both sides.](CEJU-71-1478-g003){#f0003}

Patients with other (bony or visceral) metastases were excluded. Risks, complications, alternatives as well as the current data for the salvage ePLND for 'node-only' metastatic PCa were discussed. Informed consent was signed in each case.

Robotic technique step-by-step {#sec2.1}
------------------------------

All procedures were performed by a transperitoneal approach. We did not use ureteral catheters to facilitate the intra-operative identification of the ureters, as was described by Abreu et al. \[[@cit0004]\]. Under general anesthesia a 12-mm port for the camera was placed 4 cm above the umbilicus through a midline incision by the Hassan technique. Two 8-mm robotic ports were placed on the right and left pararectal lines, 2 cm above their intersection with the umbilical line. The third 8-mm robotic port was placed 8 cm laterally to the left robotic port. The assistant port (12 mm) was placed about 8 cm laterally to the right robotic port and about 5 cm cranially to the right anterior superior iliac spine. The patient was placed in deep (35°) Trendelenburg position, the Si HD da Vinci robotic system (Intuitive Surgical, Sunnyvale, CA, USA) was docked. The anatomical limits were: the bifurcation of the common iliac arteries and ureter cranially, the Cloquet\'s lymph node caudally, the external iliac artery laterally and the bladder wall medially. We used the monopolar scissors, bipolar Maryland forceps and Prograsp.

In each case we tried to perform the eRSPLND as close to the ideal technique, described below, as possible, but in most cases the anatomy was changed due to a prior surgery. However, we are describing the step-by-step procedure:

1.  The first step is opening the peritoneum by a U incision from left to right , as in the first step of a radical prostatectomy, overlying the common iliac artery and parallel to the external iliac artery until the ureter on both sides. External iliac vessels are identified and exposed.

2.  The ureter is identified at its crossing with the common iliac artery, dissected, suspended and then displaced. Once split, the fibro-fatty tissue overlying the distal portion of the common and external iliac vessels, common iliac artery and its bifurcation are visible. The fibro-fatty tissue containing the lymphatics, overlying the internal iliac artery, its medial vesical branches and the presacral lymph nodes are identified and dissected ([Figure 4](#f0004){ref-type="fig"}).

3.  The external iliac lymph nodes are progressively dissected. Dissection is carried out from the crossing of the ureter over the common iliac artery until the pubic bone at the level of the circumflex vein that is usually preserved and dissected.

4.  The obturator fossa is reached and the lymph nodes are progressively dissected until the complete exposure of the obturator nerve. The dissection is started at the angle between the external iliac vein and the pubic bone. The lymphatic package is dissected beneath the external iliac vein, proceeding until the pelvic sidewall, which is the lateral limit of the dissection. The proximal attachments of the lymphatic packages are dissected sharp or blunt, paying attention, in order to avoid any injury to the obturator nerve. The same technique is performed contra-laterally ([Figure 5](#f0005){ref-type="fig"}).

5.  At the end of the procedure, the anterior peritoneum is sutured by a running 3-0 'barbed' suture. Hemostasis is confirmed and hemostatic agents applied as needed. A drain is placed intra-peritoneally and is usually removed on the 1^st^ postoperative day as well as the Foley catheter.

RESULTS {#sec3}
=======

The median operative time was 73.4 mins, blood loss of a 100 cc and hospital stay of 2 days. No patient had intra-operative complications, required an open conversion or any blood transfusion ([Table 2](#t0002){ref-type="table"}). Clavien II grade complications occurred in 1 patient (10%) and were managed conservatively (prolonged antibiotic treatment).

###### 

Peri-operative outcomes

  Peri-operative outcomes        Median (range) or N(%)
  ------------------------------ ------------------------
  Operative time, mins           73.4
  Estimated blood loss, ml       100
  Open conversion                0
  Blood transfusion              0
  Intra-operative complication   0
  Drain placed                   10
  Drain duration, days           1
  Hospital Stay, days            2
  Complications: Clavien II      1 (10%)

![Dissected lymph nodes.](CEJU-71-1478-g004){#f0004}

![Intraoperative picture.\
LN -- lymph node; ON -- obturatory nerve](CEJU-71-1478-g005){#f0005}

On histopathology, the median number of total and positive nodes per patient was 15 and 6, respectively. Overall, in our 10 patients, of the 157 total excised nodes, 38.8% were positive ([Table 3](#t0003){ref-type="table"}). We found a good correlation between the test results and pathology.

###### 

Pathological outcomes

  Pathological outcomes and follow-up                                                             
  ----------------------------------------------------------------------------------------------- ----------------
  No. of nodes excised/patient                                                                    
  median (range)                                                                                  15 (11--18)
  No. of positive nodes/patient                                                                   
  median (range)                                                                                  6 (4--9)
  Follow-up, days                                                                                 
  median (range)                                                                                  165 (131--350)
  Post-op PSA, ng/ml                                                                              
  median (range)                                                                                  1.1 (0.2--3.4)
  \% decrease in PSA                                                                              31.4 %
  Adjuvant hormonal therapy following eRSPLND (extended robotic salvage pelvic lymphadenectomy)   10 (100%)

The overall median (range) prostate-specific antigen (PSA) pre-eRSPLND was 3.5 (1.6--3.7) ng/ml. Three months post-operatively; the median (range) PSA was 1.1 (0.2--3.4) ng/ml. This reflects an overall median PSA decrease of 31.4%. In no patient did the post-eRSPLND PSA reach zero. The reason for that could be the presence of other undetectable lymph nodes.

DISCUSSION {#sec4}
==========

The management of patients with recurrent PCa is challenging, 20--40% of patients relapse within 5 years and 25--30% progress to metastatic disease \[[@cit0005]\]. Ultrasound and computerized imaging methods until recently did not allow to accurately determine the presence and degree of lymphadenopathy. Currently PET/CT is a perspective method of imaging for 'node-only' recurrent PCa \[[@cit0002]\].

The availability of phosphatidylcholine tumor cells in the cell membrane lead to the absorption of the radioactive material 11Choline, which is detected by PET. The sensitivity of 11Choline PET/CT is 38 -- 98% \[[@cit0005], [@cit0006], [@cit0007]\].

F. Abdollah et al., presented the results of a multicenter study comparing the PET/CT data with the subsequent histological confirmation \[[@cit0001]\]. The results of the largest-scale studies with the usage of 11C, 18F-Choline and 11C-Acetate are presented in [Table 4](#t0004){ref-type="table"}. The research made, permitted the authors to determine the sensitivity (73--95 percent), specificity (40--93 percent), positive prognosis value (86--92 percent), negative prognosis value (61--87 percent) and singularity (84--90 percent) which proved a high efficiency of this visualization method in the diagnosis of the lymph nodes involvement \[[@cit0008]--[@cit0012]\]

###### 

Literature review

  Author Year                     N    Surgery       Patients with+nodes N (%)   Mean nodes (range)   Mean+nodes (range)   PET/CT (Positron emission tomography/Computed Tomography)   Gleason score N (%)           Primary treatment N (%)           Clavien-Dindo complications                                                   Follow-up (months)
  ------------------------------- ---- ------------- --------------------------- -------------------- -------------------- ----------------------------------------------------------- ----------------------------- --------------------------------- ----------------------------------------------------------------------------- --------------------
  Schilling 2008 \[[@cit0013]\]   10   LAP           7 (70)                      7.1 (1--22)          2.8 (0--8)           \[11C\]Choline                                              \<7 8 (80) \>8 2 (20)         RP 8 (80) RT 2 (20)               NA                                                                            11
  Rinnab 2008 \[[@cit0015]\]      15   Open          8 (53.3)                    13.9 (3-45)          NR                   \[11C\]Choline                                              \<7 11 (73.3) \>8 4 (26.7)    RP 15 (100)                       NA                                                                            
  Rigatti 2011 \[[@cit0019]\]     72   Open          60 (83.3)                   30.6 (4--87)         9.08 (0--66)         \[11C\]Choline                                              \<7 45 (62.4) \>8 27 (37.6)   RP 72 (100)                       Grade 1 20.8--25% Grade 2 1.4--19.4% Grade 3a 4.1--13.8% Grade 3b 1.4--2.7%   39.4
  Jilg 2012 \[[@cit0020]\]        52   Open          47 (90.4)                   23.3 (1--57)         9.74 (0--54)         \[11C\]Choline \[18F\]Choline                               \<7 36 (69) \>8 16 (31)       RP 39 (83) RT 8 (17)              Grade 1 1.9--7.7% Grade 2 5.8% Grade 3a 3.9%                                  40.1
  Suardi 2014 \[[@cit0018]\]      59   Open          47 (79.7)                   29.5 (2--87)         8.9 (0--66)          \[11C\]Choline                                              \<7 38 (64.4) \>8 21 (35.6)   RP 59 (100)                       Grade 1 20.3--30.5% Grade 2 1.7--20.3% Grade 3a 5.1--11.2% Grade 3b 1.7%      81.1
  Tilki 2014 \[[@cit0021]\]       58   Open          45 (77.6)                   18.6 (1--88)         6.3                  \[11C\]Choline                                              \<7 30 (52) \>8 28 (48)       RP 58 (100)                       NR                                                                            39
  Jilg 2014 \[[@cit0023]\]        72   Open          72 (100)                    29.5 (2--111)        9.5 (0--81)          \[11C\]Choline \[18F\]Choline                               \<7 34 (47) \>8 32 (48)       RP 63 (87.5) RT 8 (12.5)          NR                                                                            32
  Winter 2015 \[[@cit0024]\]      13   Open          11 (84.6)                   NR                   1 (0--3)             \[11C\]Choline \[18F\]Choline                               \<7 8 (61.5) \>8 3 (23)       RP 13 (100)                       Grade 3b 1(6.7%)                                                              31
  Karnes 2015 \[[@cit0025]\]      52   Open          52 (100)                    23.8 (16--30)        5.3 (1--31)          \[11C\]Choline                                              \<7 30 (57.7) \>8 19(36.5)    RP 52 (100)                       Grade 2 1.9% Grade 3a 1.9% Grade 3b 1.9%                                      20.9
  Clayes 2014 \[[@cit0005]\]      17   Open LAP RA   15 (88.2)                   11.8 (1--21)         2.3 (0--6)           \[11C\]Choline \[18F\]Choline                               \<7 9 (53) \>8 8 (47)         RP 14 (82) RT 8 (17) HIFU 1 (6)   Grade 1 35% Crade 2 6% Grade 3a 6--12%                                        22
  Abreu2016 \[[@cit0004]\]        10   RA            7 (70%)                     83 (41--132)         26 (0--109)          \[11C\]Acetate                                              \<7 4 (40) \>8 6 (60)         RP 8 (80) RT 2 (20)               Grade1 10% Grade2 10%                                                         2
  Current Study                   10   RA            10 (100%)                   15 (11--18)          6 (4--9)             \[11C\]Choline                                              \<7 7 (70) \>8 3 (30)         RP 10 (100%)                      Grade 2 20%                                                                   3

D. Schilling et al., analyzed the results of 10 patients, who underwent radiotherapy or radical prostatectomy with further laparoscopic dissection of lymph nodes (which were suspicious during PET/CT with 11Choline). In this paper only in 7 cases of PCa were confirmed by histology \[[@cit0013]\].

J. Winter et al., presented the results of a salvage pelvic lymphadenectomy in 6 patients with 'node-only' PCa recurrence on the PET/CT. The average PSA was 2.04 (0.67--4.51) ng/ml. During the histopathological examination of the removed lymph nodes, prostate cancer was verified in all patients \[[@cit0014]\].

Results of the salvage pelvic lymphadenectomy of 15 patients with PCa recurrence confirmed by PET/CT were presented by L. Rinnab et al. None of the patients had any data regarding the availability of local recurrence or distant metastases. The average level of total PSA was 1.7 ng/ml, average number of removed lymph nodes during the extended pelvic lymphadenectomy -13.9. Median follow-up time was 13.7 months \[[@cit0015]\].

The possibility of a reliable visualization of the PCa node-only recurrence by 11Choline PET/CT, depends upon several factors, including the PSA level prior to the examination. Thus, according to the opinion of I. de Jong et al., the PET/CT should not be prescribed to patients with PSA level is \<5.0 ng/ml because of high false-negative results \[[@cit0006]\]. However, the subsequent studies that evaluate the usage of PET/CT for patients with PSA level \<0.5 ng/ml obtained no data pertaining to the false-negative results \[[@cit0016]\]. M. Mamede et al., remarked that besides the PSA level the result of the examination is also influenced by the hormonal treatment \[[@cit0017]\].

Salvage lymphadenectomy has been performed in over 500 patients reported in 11 publications to date ([Table 4](#t0004){ref-type="table"}). At 8 years, clinical recurrence- -free survival and cancer-specific mortality-free survival were 38% and 81%, respectively \[[@cit0018]\]. Only two papers evaluated laparoscopic/robotic surgery \[[@cit0005], [@cit0013]\]. This series showed comparable results with our study in terms of complication rates and the median number of total and positive lymph nodes per patient \[[@cit0022]\].

To our knowledge this is one of the largest series of robotic salvage ePLND for 'node-only' recurrent PCa. Abreu et al., reported ten cases of robotic salvage RPLND+PLND for positive lymph node recurrent PCa \[[@cit0004]\]. In this study the mean number of total and positive nodes per patient was 83 (41--132) and 23 (0--109), respectively. Such a large number of removed lymph nodes, was due to much more extended lymph node dissection than in our study. However, authors reported positive nodes on the final histology in 7 out of 10 cases. We found positive lymph nodes in all ten cases. Moreover, we found a good correlation between the test results and the pathology report.

Clayes et al., reported about 17 cases of salvage lymphadenectomy, but robot-assisted technique was used only in 6 patients. All intraoperative outcomes were comparable to our results (number of removed and positive nodes, complication rate and so on) \[[@cit0005]\].

We present our technique for performing the eRSPLND. No major intra-operative complications occurred. This is definitely a challenging procedure and should be performed only in specialized centers with great experience of robot-assisted surgery. One of the possible limitations of our study was the use of the 11Choline PET/CT. Prostate-specific membrane antigen (PSMA) PET/CT was not available at that time. To access the long-term oncological outcome a larger cohort with longer follow-up period is needed.

CONCLUSIONS {#sec5}
===========

The salvage extended pelvic lymphadenectomy is mostly justified for patients with the PSA level \<4 ng/ml, Gleason score ≤7 with 'node-only' PCa recurrence. This procedure allows the majority of patients to postpone hormonal treatment, which can theoretically decrease cost of the treatment. Choline PET/CT identifies patients appropriate for the eRSPLND. Longer follow-up is necessary to assess the oncologic outcomes.
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